Residency · Residency · Otolaryngology

Salivary Gland Neoplasms: Workup and Classification

Introduction

Salivary gland neoplasms represent a diverse group of tumors with a wide spectrum of biological behavior. They account for approximately 3-6% of all head and neck neoplasms. The fundamental rule in salivary gland oncology is that the smaller the gland, the higher the probability of malignancy. A thorough understanding of classification, workup, and histopathology is critical for appropriate management.

Anatomy Review

Parotid gland: largest salivary gland; Stensen duct opens opposite the second upper molar. Submandibular gland: Wharton duct opens at the sublingual caruncle. Sublingual gland: drains via multiple ducts of Rivinus into the floor of mouth. Minor salivary glands: 600-1000 distributed throughout the oral cavity, pharynx, larynx, and sinonasal tract; palate is the most common site of minor salivary gland tumors.

Epidemiology

80% of salivary neoplasms occur in the parotid gland. Of parotid tumors, 80% are benign. Of submandibular tumors, approximately 50% are malignant. Of minor salivary gland tumors, approximately 50-80% are malignant. The "80-80 rule": 80% of salivary tumors arise in the parotid, and 80% of those are benign.

Classification of Salivary Gland Neoplasms

Benign Tumors

Pleomorphic adenoma (benign mixed tumor): most common salivary neoplasm overall (60-70%); composed of epithelial and mesenchymal elements; risk of malignant transformation (carcinoma ex pleomorphic adenoma) with prolonged observation. Warthin tumor (papillary cystadenoma lymphomatosum): second most common benign parotid tumor; bilateral in 10-15%; more common in smokers and males. Oncocytoma: rare, composed of mitochondria-rich oncocytes. Basal cell adenoma and canalicular adenoma.

Malignant Tumors

Mucoepidermoid carcinoma: most common malignant salivary neoplasm; low, intermediate, and high grade; low grade has excellent prognosis. Adenoid cystic carcinoma: characterized by perineural invasion; three patterns — cribriform (best prognosis), tubular, and solid (worst prognosis); late distant metastases (lung) even decades after treatment. Acinic cell carcinoma: low-grade malignancy; most common in the parotid. Salivary duct carcinoma: high-grade, aggressive; resembles ductal breast carcinoma; often androgen receptor positive. Carcinoma ex pleomorphic adenoma: arises within a longstanding pleomorphic adenoma; prognosis depends on extent of invasion beyond the capsule. Adenocarcinoma NOS and polymorphous adenocarcinoma.

Clinical Presentation

Painless mass in the parotid, submandibular, or oral cavity region. Pain: suggests malignancy or infection but is not specific. Facial nerve weakness: highly suspicious for malignant parotid tumor. Rapid growth: concerning for high-grade malignancy or lymphoma. Fixation to skin or underlying structures: suggests malignancy. Cervical lymphadenopathy: present in 15-25% of malignant cases.

Diagnostic Workup

Imaging

Ultrasound: first-line; differentiates solid from cystic lesions; guides FNA. CT with contrast: assesses deep lobe tumors, bony invasion, nodal disease. MRI with gadolinium: superior soft tissue detail; evaluates perineural spread (adenoid cystic carcinoma). PET-CT: for staging high-grade malignancies.

Fine Needle Aspiration (FNA)

Sensitivity 85-95%, specificity 95-100% for distinguishing benign from malignant. Milan System for Reporting Salivary Gland Cytopathology: standardized reporting categories (non-diagnostic, non-neoplastic, atypia of undetermined significance, benign, SUMP, suspicious, malignant). Core needle biopsy may be considered when FNA is non-diagnostic.

Staging (AJCC 8th Edition)

Based on tumor size, extraparenchymal extension, and involvement of adjacent structures. T1: <=2 cm, T2: 2-4 cm, T3: >4 cm or extraparenchymal extension, T4a/b: skin, mandible, ear canal, facial nerve, skull base invasion. Nodal staging follows standard head and neck N classification. High-grade histology is the most important prognostic factor independent of stage.

Management Principles

Benign tumors: surgical excision (superficial or total parotidectomy with facial nerve preservation). Malignant tumors: surgery with appropriate margins +/- neck dissection +/- adjuvant radiation. Facial nerve: preserved unless directly invaded by tumor. Adjuvant radiation: indicated for high-grade histology, close/positive margins, perineural invasion, T3-T4, nodal disease. Chemotherapy: limited role; reserved for recurrent/metastatic disease. Androgen receptor blockade: emerging role for salivary duct carcinoma.

Key Clinical Pearls

The smaller the gland, the higher the likelihood of malignancy — always biopsy minor salivary gland lesions. Pleomorphic adenomas should be excised, not enucleated, due to pseudopod extensions through the capsule and risk of recurrence. Adenoid cystic carcinoma has a propensity for perineural invasion and late distant metastases; long-term follow-up (15-20 years) is essential. Facial nerve paralysis with a parotid mass is malignancy until proven otherwise. FNA is the initial tissue sampling modality of choice; incisional biopsy of parotid masses should be avoided.

References

1. Speight PM, Barrett AW. Salivary gland tumours: diagnostic challenges and an update on the latest WHO classification. Diagn Histopathol. 2020;26(4):147-158.
2. Stodulski D, Mikaszewski B, Stankiewicz C. Signs and symptoms of parotid gland carcinoma and their prognostic value. Int J Oral Maxillofac Surg. 2012;41(7):801-806.
3. Rossi ED, Wong LQ, Bizzarro T, et al. The Milan System for Reporting Salivary Gland Cytopathology. Cancer Cytopathol. 2018;126(10):757-766.
4. Andreasen S, Therkildsen MH, Grauslund M, et al. Salivary gland neoplasms: an overview of the current WHO classification. Head Neck Pathol. 2021;15(2):394-406.

For the intern

At 3am, your priority is ruling out acute complications: facial nerve weakness (suggests malignancy), rapidly enlarging mass (high-grade tumor or infection), or airway compromise from a large mass. Order stat imaging if airway threatened and involve ENT immediately. Most salivary masses are subacute and can wait until morning for ultrasound and FNA scheduling. Never attempt incisional biopsy of a parotid mass yourself—this risks tumor seeding and facial nerve injury.

Common pitfalls

• Assuming pain equals benign disease: Pain can occur with malignancy, particularly with perineural invasion in adenoid cystic carcinoma. Always pursue tissue diagnosis regardless of symptoms.

• Delaying workup of submandibular or minor salivary gland masses: Remember the inverse relationship—smaller glands have higher malignancy rates (50-80%). A palate mass is malignant until proven otherwise.

• Forgetting long-term follow-up for adenoid cystic carcinoma: This tumor metastasizes to lungs years or even decades after treatment. Schedule surveillance imaging extending 15-20 years.

• Ordering incisional biopsy instead of FNA: Ultrasound-guided FNA (sensitivity 85-95%) is the gold standard for tissue sampling. Incisional biopsy risks tumor seeding and facial nerve injury in parotid masses.

Make it stick

You're covering the emergency department overnight when a patient presents with a slowly growing parotid mass. They report mild discomfort but no facial weakness or rapid changes. The temptation is to reassure them and send them home, scheduling follow-up in a week. Instead, recall that while most parotid masses are benign, approximately 20% are malignant. Importantly, the absence of overt "red flags" like facial nerve palsy doesn't rule out malignancy, as many malignant salivary tumors present as painless, slow-growing masses. Document a thorough history and physical, specifically noting facial nerve function, and ensure appropriate outpatient imaging (ultrasound, MRI) and fine needle aspiration (FNA) are ordered promptly. Your diligence ensures early diagnosis and optimal management, potentially preventing a benign mass from becoming more aggressive or identifying malignancy at an earlier, more treatable stage.

If you remember one thing

Always remember the "80-80 rule": 80% of salivary gland tumors occur in the parotid, and 80% of those are benign, but the remaining 20% can be aggressive. Fine needle aspiration (FNA) is your best initial diagnostic tool, as incisional biopsy of a parotid mass risks tumor seeding and facial nerve injury.

Read this lecture as Markdown